PLATFORM TECHNOLOGIES

The company's proprietary platform technologies are based on the discovery of a novel tumor-specific marker - membrane heat shock protein 70 (Hsp70).

Membrane Hsp70 is most frequently expressed on a variety of different tumor types including lung, colon, breast, head and neck, stomach, pancreas carcinomas, malignant melanoma, and hematological diseases, but never on the corresponding normal tissues. In addition to primary tumors, metastases, the major cause of death by cancer, present even higher amounts of Hsp70 on their surface membranes. Metastatic disease is responsible for approximately 90% of all cancer-related deaths.

Based on its discovery of membrane Hsp70, multimmune has developed a unique and powerful approach which programs human natural killer (NK) cells to recognize and kill cancers expressing membrane Hsp70. These cells destroy tumors and metastases that are invisible to the cell killing (cytolytic) consequences of T cell immunotherapies.

Tumors expressing membrane Hsp70 can also be recognized and targeted using unique, proprietary 14mer peptide (mi-TPP), monoclonal antibody (cmHsp70.1, mi-TUMEXtx) and recombinant granzyme B (mi-APO), all of which can detect membrane Hsp70.